Accelerating medical cost inflation, strained combined ratios, and rising protection gap demands urgent joint action from governments, regulators and insurers.
The development highlights ongoing regulatory efforts to address cost pressures and execution challenges in India’s rapidly growing private health insurance market.
The Shield MCD test screens for 10 of the most common cancers — bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian, and pancreatic — with just a blood draw.
The budget outlines support for new insurance solvency rules and greater disclosure standards, but focus on growth sectors—such as low-altitude aviation and autonomous vehicles—will bring new opportunities...
The scheme shifts Religare’s lending, broking, and investment operations into Religare Finvest, with a separate listing targeted for Q1 FY28, subject to approvals.
